Quantcast

Medivisor Inc. Announces New Sales and Marketing Agreement for Mucotrol(TM) With Cura Pharmaceutical Co Inc.

July 24, 2008

Medivisor Inc. (PINKSHEETS: MVSR) today announced that it has signed a new sales and marketing agreement with Cura Pharmaceutical for the marketing of Mucotrol(TM) in the United States. The groundbreaking drug Mucotrol(TM) is an oral gel wafer that received 510-K approval as a device from the FDA in late November 2004, as a treatment for mouth sores related to chemotherapy.

Cura will supply and distribute Mucotrol(TM) with Medivisor handling the marketing and sales. Under the terms of the new agreement both parties agree to now share in the net profits.

“We are pleased to have signed this new sales and marketing agreement with Cura,” stated Dino Luzzi, CEO of Medivisor. “We believe Mucotrol will demonstrate strong commercial interest in the relief of side effects of those patients undergoing chemotherapy treatments.”

About Medivisor Inc.: Medivisor is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Medivisor exclusively serves the bioscience and pharmaceutical markets, offering specialized medical marketing consulting, graphic design, web site marketing strategy and market research.

About Cura Pharmaceutical: Cura is a privately held pharmaceutical business that develops, distributes and sells innovative and generic pharmaceuticals. It focuses on selected niche specialty markets through the offering of distinctive products and services, which provide distinct unmet medical needs.

About Mucotrol(TM): Mucotrol(TM) is prescribed for the management and relief of pain for Mucositis, which may be caused by chemotherapy or radiotherapy and irritation due to oral surgery. The National Cancer Institute estimates that approximately 300,000 cancer patients in the U.S. suffer from mucositis associated with cancer treatments.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”) including those relating to the roll-out of Cura Pharmaceutical’s Mucotrol. Additionally, words such as “seek,”"intend,”"believe,”"plan,”"estimate,”"expect,”"anticipate” and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.

 Contact: Dino Luzzi CEO Medivisor Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100 Email Contact

SOURCE: Medivisor Inc.




comments powered by Disqus